JP2019142911A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019142911A5 JP2019142911A5 JP2019076111A JP2019076111A JP2019142911A5 JP 2019142911 A5 JP2019142911 A5 JP 2019142911A5 JP 2019076111 A JP2019076111 A JP 2019076111A JP 2019076111 A JP2019076111 A JP 2019076111A JP 2019142911 A5 JP2019142911 A5 JP 2019142911A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- composition
- composition according
- compound
- cancer vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 7
- 229940022399 cancer vaccine Drugs 0.000 claims 5
- 238000009566 cancer vaccine Methods 0.000 claims 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 3
- -1 phosphorothioate diester Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 2
- 150000004713 phosphodiesters Chemical class 0.000 claims 2
- MFEFTTYGMZOIKO-UHFFFAOYSA-N 5-azacytosine Chemical group NC1=NC=NC(=O)N1 MFEFTTYGMZOIKO-UHFFFAOYSA-N 0.000 claims 1
- 108010044267 Abnormal Hemoglobins Proteins 0.000 claims 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims 1
- 208000019838 Blood disease Diseases 0.000 claims 1
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 102100032937 CD40 ligand Human genes 0.000 claims 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 1
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 claims 1
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 1
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 claims 1
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 1
- 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 claims 1
- 101001057156 Homo sapiens Melanoma-associated antigen C2 Proteins 0.000 claims 1
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 claims 1
- 101000972276 Homo sapiens Mucin-5B Proteins 0.000 claims 1
- 101000874141 Homo sapiens Probable ATP-dependent RNA helicase DDX43 Proteins 0.000 claims 1
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 101000814512 Homo sapiens X antigen family member 1 Proteins 0.000 claims 1
- 102100031520 MAPK/MAK/MRK overlapping kinase Human genes 0.000 claims 1
- 102100027252 Melanoma-associated antigen C2 Human genes 0.000 claims 1
- 102100034263 Mucin-2 Human genes 0.000 claims 1
- 102100022494 Mucin-5B Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000036673 PRAME Human genes 0.000 claims 1
- 108060006580 PRAME Proteins 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 102100035724 Probable ATP-dependent RNA helicase DDX43 Human genes 0.000 claims 1
- 102100037686 Protein SSX2 Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 102100039490 X antigen family member 1 Human genes 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000005690 diesters Chemical class 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000004437 phosphorous atom Chemical group 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 0 *C1[C@](N(C=NC(N)=N2)C2=O)O[C@](CO)C1OP(*)(OC[C@](C(C1*=C)N)O[C@@]1[n]1c(N=C(*)NC2=O)c2nc1)=O Chemical compound *C1[C@](N(C=NC(N)=N2)C2=O)O[C@](CO)C1OP(*)(OC[C@](C(C1*=C)N)O[C@@]1[n]1c(N=C(*)NC2=O)c2nc1)=O 0.000 description 4
- HVHZDGNAWQEZRD-LFYCGXNYSA-N COC1[C@H](N(C=[N+](C(N)=N2)[O-]C3[C@H]([n]4c(N=C(N)NC5=O)c5nc4)O[C@H](CO)C3OP(O)(OC3)=O)C2=O)O[C@H]3C1O Chemical compound COC1[C@H](N(C=[N+](C(N)=N2)[O-]C3[C@H]([n]4c(N=C(N)NC5=O)c5nc4)O[C@H](CO)C3OP(O)(OC3)=O)C2=O)O[C@H]3C1O HVHZDGNAWQEZRD-LFYCGXNYSA-N 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361771525P | 2013-03-01 | 2013-03-01 | |
| US61/771,525 | 2013-03-01 | ||
| US201361887165P | 2013-10-04 | 2013-10-04 | |
| US61/887,165 | 2013-10-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560330A Division JP6514647B2 (ja) | 2013-03-01 | 2014-02-27 | 薬物組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019142911A JP2019142911A (ja) | 2019-08-29 |
| JP2019142911A5 true JP2019142911A5 (enExample) | 2019-12-26 |
Family
ID=50288308
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560330A Expired - Fee Related JP6514647B2 (ja) | 2013-03-01 | 2014-02-27 | 薬物組み合わせ |
| JP2019076111A Pending JP2019142911A (ja) | 2013-03-01 | 2019-04-12 | 薬物組み合わせ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560330A Expired - Fee Related JP6514647B2 (ja) | 2013-03-01 | 2014-02-27 | 薬物組み合わせ |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20160015805A1 (enExample) |
| EP (2) | EP3563836A1 (enExample) |
| JP (2) | JP6514647B2 (enExample) |
| KR (1) | KR20150125963A (enExample) |
| CN (2) | CN105025884B (enExample) |
| AU (1) | AU2014223348B2 (enExample) |
| CA (1) | CA2902433A1 (enExample) |
| CY (1) | CY1122554T1 (enExample) |
| DK (1) | DK2961388T3 (enExample) |
| ES (1) | ES2734023T3 (enExample) |
| HR (1) | HRP20191171T1 (enExample) |
| HU (1) | HUE044430T2 (enExample) |
| IL (2) | IL240894B (enExample) |
| LT (1) | LT2961388T (enExample) |
| MX (2) | MX366967B (enExample) |
| PH (2) | PH12015501905A1 (enExample) |
| PL (1) | PL2961388T3 (enExample) |
| PT (1) | PT2961388T (enExample) |
| RU (2) | RU2019138702A (enExample) |
| SA (1) | SA515360959B1 (enExample) |
| SG (2) | SG10201707135RA (enExample) |
| SI (1) | SI2961388T1 (enExample) |
| WO (1) | WO2014134355A1 (enExample) |
| ZA (2) | ZA201506150B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| HUE042327T2 (hu) | 2011-08-30 | 2019-06-28 | Astex Pharmaceuticals Inc | Decitabin-származék készítmények |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| ES3040431T3 (en) | 2014-03-12 | 2025-10-31 | Yeda Res & Dev | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
| ES2749098T3 (es) * | 2014-05-13 | 2020-03-19 | Medimmune Ltd | Anticuerpos ANTI-B7-H1 y ANTI-CTLA-4 para tratar el cáncer de pulmón no microcítico |
| WO2016010879A1 (en) * | 2014-07-15 | 2016-01-21 | The Johns Hopkins University | Suppression of myeloid derived suppressor cells and immune checkpoint blockade |
| BR112017006969A2 (pt) | 2014-10-07 | 2017-12-19 | Cytlimic Inc | peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno |
| WO2016061231A1 (en) * | 2014-10-14 | 2016-04-21 | Deciphera Pharmaceuticals, Llc | Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression |
| US10525035B2 (en) | 2014-12-18 | 2020-01-07 | Lankenau Institute For Medical Research | Methods and compositions for the treatment of retinopathy and other ocular diseases |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| TW202115102A (zh) | 2015-03-09 | 2021-04-16 | 日商賽多利克公司 | 來自gpc3之胜肽、使用此胜肽之用於治療或預防癌症之醫藥組成物、免疫誘導劑、及抗原呈現細胞之製造方法 |
| ES2844049T3 (es) * | 2015-04-07 | 2021-07-21 | Cytlimic Inc | Adyuvante para vacunas contra el cáncer |
| US10485764B2 (en) * | 2015-07-02 | 2019-11-26 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized pharmaceutical compositions |
| BR112019006075A2 (pt) | 2016-10-11 | 2019-06-18 | Cytlimic Inc | medicamento |
| GB201704966D0 (en) * | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| CN111182908A (zh) | 2017-08-03 | 2020-05-19 | 大塚制药株式会社 | 药物化合物及其纯化方法 |
| EP3727374A4 (en) * | 2017-12-21 | 2021-11-10 | Merck Patent GmbH | COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND AN IDO1 INHIBITOR FOR THE TREATMENT OF CANCER |
| CN108948203B (zh) * | 2018-08-09 | 2019-06-04 | 南京鼓楼医院 | 抗pd-1单克隆抗体及其制备方法和应用 |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| AU2021261676B2 (en) * | 2020-04-24 | 2025-04-24 | Genexine, Inc. | Method for treating cervical cancer |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
| TR200002284T2 (tr) | 1998-02-05 | 2000-11-21 | Smithkline Beecham Biologicals S.A. | Mage ailesinden tümör ile ilgili tümör türevleri |
| DK2112166T3 (en) | 1998-12-23 | 2019-02-04 | Pfizer | Human monoclonal antibodies to CTLA-4 |
| GB9908885D0 (en) * | 1999-04-19 | 1999-06-16 | Smithkline Beecham Biolog | Vccine |
| CN1227030C (zh) * | 1999-04-19 | 2005-11-16 | 史密丝克莱恩比彻姆生物有限公司 | 包含皂甙和免疫刺激寡核苷酸的佐剂组合物 |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US6613753B2 (en) * | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| US20030148973A1 (en) | 2001-05-23 | 2003-08-07 | Peter Emtage | MAGE-A1 peptides for treating or preventing cancer |
| AU2003243485A1 (en) * | 2002-06-10 | 2003-12-22 | Avax Technologies Inc. | Cryopreservation of haptenized tumor cells |
| WO2005033278A2 (en) | 2003-09-30 | 2005-04-14 | Ludwig Institute For Cancer Research | In vivo efficacy of ny-eso-1 plus iscom |
| WO2005115450A1 (en) * | 2004-05-26 | 2005-12-08 | Biovaxim Limited | Compositions comprising demethylating agents as enhancers of immunotherapy for the treatment of chronic infections and neoplastic diseases and methods for treating the same |
| JP2008518902A (ja) | 2004-11-04 | 2008-06-05 | ファイザー・プロダクツ・インク | 乳癌のためのｃｔｌａ４抗体とアロマターゼ阻害剤の併用治療 |
| EP1833506B1 (en) | 2004-12-29 | 2015-08-26 | Mannkind Corporation | Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines |
| CA2593191A1 (en) * | 2005-01-14 | 2006-07-20 | Avax Technologies, Inc. | Method for producing a vaccine for the treatment of cancer |
| ES2720160T3 (es) | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| PL1928492T3 (pl) * | 2005-09-01 | 2011-09-30 | Celgene Corp | Immunologiczne zastosowania związków immunomodulujących do szczepionki i przeciwzakaźnego leczenia choroby |
| US7700567B2 (en) * | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| MX342945B (es) * | 2009-07-06 | 2016-10-18 | Ontorii Inc * | Profármacos de ácido nucleico novedosos y métodos de uso de los mismos. |
| LT2769737T (lt) * | 2009-07-20 | 2017-06-26 | Bristol-Myers Squibb Company | Anti-ctla4 antikūno derinys su etopozidu, skirtas sinerginiam proliferacinių ligų gydymui |
| US20120277158A1 (en) * | 2009-10-06 | 2012-11-01 | Angiochem Inc. | Compositions and methods for the transport of therapeutic agents |
| GB201006096D0 (en) * | 2010-04-13 | 2010-05-26 | Alligator Bioscience Ab | Novel compositions and uses thereof |
| JP6121904B2 (ja) | 2010-09-08 | 2017-04-26 | ハロザイム インコーポレイテッド | 条件的活性治療用タンパク質を評価および同定する、または発展させる方法 |
| KR20140029446A (ko) * | 2011-04-15 | 2014-03-10 | 컴퓨젠 엘티디. | 면역 관련 장애 및 암의 치료를 위한 폴리펩티드 및 폴리뉴클레오티드, 및 이들의 용도 |
| HUE042327T2 (hu) * | 2011-08-30 | 2019-06-28 | Astex Pharmaceuticals Inc | Decitabin-származék készítmények |
| US11083743B2 (en) * | 2013-02-21 | 2021-08-10 | Michele Maio | DNA hypomethylating agents for cancer therapy |
-
2014
- 2014-02-27 DK DK14710728.8T patent/DK2961388T3/da active
- 2014-02-27 WO PCT/US2014/019137 patent/WO2014134355A1/en not_active Ceased
- 2014-02-27 CN CN201480011754.5A patent/CN105025884B/zh not_active Expired - Fee Related
- 2014-02-27 US US14/771,011 patent/US20160015805A1/en not_active Abandoned
- 2014-02-27 ES ES14710728T patent/ES2734023T3/es active Active
- 2014-02-27 SI SI201431263T patent/SI2961388T1/sl unknown
- 2014-02-27 PT PT14710728T patent/PT2961388T/pt unknown
- 2014-02-27 CA CA2902433A patent/CA2902433A1/en not_active Abandoned
- 2014-02-27 EP EP19163282.7A patent/EP3563836A1/en not_active Withdrawn
- 2014-02-27 KR KR1020157025503A patent/KR20150125963A/ko not_active Ceased
- 2014-02-27 AU AU2014223348A patent/AU2014223348B2/en not_active Ceased
- 2014-02-27 SG SG10201707135RA patent/SG10201707135RA/en unknown
- 2014-02-27 CN CN201910760009.5A patent/CN110448566A/zh active Pending
- 2014-02-27 HU HUE14710728 patent/HUE044430T2/hu unknown
- 2014-02-27 PL PL14710728T patent/PL2961388T3/pl unknown
- 2014-02-27 RU RU2019138702A patent/RU2019138702A/ru unknown
- 2014-02-27 MX MX2015011147A patent/MX366967B/es active IP Right Grant
- 2014-02-27 RU RU2015141628A patent/RU2708246C2/ru active
- 2014-02-27 SG SG11201506727RA patent/SG11201506727RA/en unknown
- 2014-02-27 EP EP14710728.8A patent/EP2961388B1/en active Active
- 2014-02-27 JP JP2015560330A patent/JP6514647B2/ja not_active Expired - Fee Related
- 2014-02-27 HR HRP20191171TT patent/HRP20191171T1/hr unknown
- 2014-02-27 LT LTEP14710728.8T patent/LT2961388T/lt unknown
-
2015
- 2015-08-24 ZA ZA201506150A patent/ZA201506150B/en unknown
- 2015-08-27 IL IL240894A patent/IL240894B/en active IP Right Grant
- 2015-08-27 MX MX2019008822A patent/MX2019008822A/es unknown
- 2015-08-28 PH PH12015501905A patent/PH12015501905A1/en unknown
- 2015-08-30 SA SA515360959A patent/SA515360959B1/ar unknown
-
2019
- 2019-04-12 JP JP2019076111A patent/JP2019142911A/ja active Pending
- 2019-07-10 CY CY20191100738T patent/CY1122554T1/el unknown
- 2019-07-17 US US16/514,377 patent/US20200009247A1/en not_active Abandoned
- 2019-08-16 ZA ZA2019/05426A patent/ZA201905426B/en unknown
- 2019-10-17 PH PH12019550222A patent/PH12019550222A1/en unknown
-
2020
- 2020-09-15 IL IL277385A patent/IL277385A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019142911A5 (enExample) | ||
| RU2019138702A (ru) | Комбинации лекарственных средств | |
| JP2013518116A5 (enExample) | ||
| JP2019522055A5 (enExample) | ||
| JP2015535831A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| ES2703257T3 (es) | Compuestos y composiciones para el tratamiento del cáncer | |
| JP2017508789A5 (enExample) | ||
| JP2014528466A5 (enExample) | ||
| JP2009541236A5 (enExample) | ||
| JP2016510030A5 (enExample) | ||
| RU2012136468A (ru) | Производные фуро[3,2,-в]пирана, применимые в синтезе аналогов | |
| JP2005504749A5 (enExample) | ||
| JP2005502635A5 (enExample) | ||
| JP2002514161A (ja) | ガンおよび他の細胞増殖性疾患の治療に有用なレチノイルオキシ（置換）アルキレンブチレート | |
| JP2016515128A5 (enExample) | ||
| JP2015512943A5 (enExample) | ||
| JP2008510778A5 (enExample) | ||
| CY1108498T1 (el) | Συνθεση εμβολιου η οποια περιεχει ως εκδοχο μια αλκυλφωσφατιδυλοχολινη | |
| JP2013536227A5 (enExample) | ||
| JP2016536360A5 (enExample) | ||
| JP2009167162A5 (enExample) | ||
| JP2022533020A (ja) | がん免疫療法アジュバント | |
| JP2010531855A5 (enExample) | ||
| JP2011513471A5 (enExample) |